BAX 855 enters Phase II/III study for Haemophilia
Baxter International Inc. has announced it has submitted an Investigational New Drug (IND) application for its investigational Haemophilia A treatment, BAX 855, with the FDA following positive results from a Phase I trial. BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of Advate [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] - the most widely chosen rFVIII in the world.
Baxter expects to start enrollment of adult patients in its Phase II/III study in the first quarter of 2013. BAX 855 has the potential to maintain the safety profile and meaningfully extend the half-life of Advate to allow for less frequent dosing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.